Pharmacokinetics of isepamicin

Area of Science:

• Pharmacology
• Microbiology
• Clinical Pharmacy

Background:

• Isepamicin is a novel aminoglycoside antibiotic with demonstrated activity against bacteria resistant to other aminoglycosides.
• Understanding its pharmacokinetic profile is crucial for optimizing therapeutic use, particularly in diverse patient populations.

Purpose of the Study:

• To characterize the pharmacokinetics of isepamicin across various human populations, including neonates, pediatrics, adults, the elderly, and renally impaired individuals.
• To compare isepamicin's pharmacokinetic properties with those of existing aminoglycosides.

Main Methods:

• Population pharmacokinetic techniques were employed to analyze data from clinical trials.
• Drug absorption, metabolism, distribution, and elimination were assessed in different demographic and clinical groups.

Main Results:

• Isepamicin is well-absorbed intramuscularly, not metabolized, and eliminated renally, necessitating dose adjustments in renal impairment.
• Pharmacokinetics are generally linear and dose-independent, with a half-life of 2-2.5 hours, showing no significant accumulation with once- or twice-daily dosing.
• The drug distributes to extracellular fluid and pulmonary tissue, with preliminary data suggesting potentially less tissue accumulation than other aminoglycosides.

Conclusions:

• Isepamicin exhibits predictable linear pharmacokinetics, consistent with other aminoglycosides.
• Potential for decreased tissue accumulation supports the consideration of once-daily dosing regimens for isepamicin.